Amir Kazmi Purchases 2,545 Shares of Ralliant (NYSE:RAL) Stock

Ralliant Corporation (NYSE:RAL) SVP Amir Kazmi bought 2,545 shares of the business’s stock in a transaction on Friday, February 6th. The stock was purchased at an average cost of $39.27 per share, for a total transaction of $99,942.15. Following the transaction, the senior vice president owned 39,699 shares of the company’s stock, valued at $1,558,979.73. This trade represents a 6.85% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ralliant Trading Up 4.7%

RAL opened at $43.11 on Wednesday. Ralliant Corporation has a 52 week low of $37.27 and a 52 week high of $57.02. The business has a fifty day simple moving average of $51.26 and a 200-day simple moving average of $46.64. The firm has a market cap of $4.86 billion and a P/E ratio of 33.94. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.02. The firm had revenue of $554.60 million during the quarter, compared to analysts’ expectations of $543.04 million. The company’s revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, March 9th. Ralliant’s dividend payout ratio is currently 15.75%.

Wall Street Analyst Weigh In

RAL has been the topic of several recent research reports. Vertical Research raised shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research note on Friday, February 6th. Oppenheimer dropped their price target on shares of Ralliant from $60.00 to $50.00 and set an “outperform” rating for the company in a research note on Friday. Barclays reduced their price objective on Ralliant from $60.00 to $52.00 and set an “overweight” rating on the stock in a research note on Monday. Royal Bank Of Canada lowered their target price on Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday. Finally, Morgan Stanley restated an “overweight” rating and set a $45.00 price target on shares of Ralliant in a report on Friday. Seven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Ralliant has an average rating of “Moderate Buy” and a consensus price target of $50.50.

Institutional Investors Weigh In On Ralliant

A number of hedge funds and other institutional investors have recently modified their holdings of RAL. Vanguard Group Inc. increased its position in shares of Ralliant by 10.7% during the third quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company’s stock worth $637,995,000 after purchasing an additional 1,415,327 shares in the last quarter. Dodge & Cox purchased a new position in Ralliant during the 2nd quarter worth approximately $523,571,000. Viking Global Investors LP acquired a new position in Ralliant during the second quarter worth approximately $257,200,000. State Street Corp purchased a new stake in Ralliant in the second quarter valued at approximately $213,096,000. Finally, Flossbach Von Storch SE lifted its stake in Ralliant by 1.7% in the third quarter. Flossbach Von Storch SE now owns 4,152,866 shares of the company’s stock valued at $181,605,000 after buying an additional 67,963 shares during the last quarter.

Key Stories Impacting Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Multiple insider purchases (SVP Amir Kazmi, Director Kevin Bryant and others) signal management confidence and provide a buy signal to some investors. Read More. Read More.
• Positive Sentiment: Research upgrades (Vertical Research upgraded RAL) can attract buyers and support near‑term demand. Read More.
• Neutral Sentiment: Barclays lowered its price target (from $60 to $52) but kept an Overweight rating — still implies upside but reduces near‑term enthusiasm. Read More.
• Neutral Sentiment: Citigroup trimmed its target to $51 — a modest negative to sentiment but still above current trading levels. Read More.
• Negative Sentiment: Ralliant reported a $1.4 billion non‑cash goodwill impairment in its Test & Measurement segment and reduced FY2026 outlook — a substantive charge that led to analyst re‑ratings and is a key fundamental negative. Read More.
• Negative Sentiment: Multiple law firms (including Levi & Korsinsky, Kessler Topaz, Kirby McInerney, Bragar Eagel & Squire and Kaplan Fox) have opened or publicized investigations into potential securities‑law violations tied to the timing and disclosure of the impairment and guidance — this raises regulatory, litigation and reputational risk. Read More.
• Negative Sentiment: Short interest jumped ~58.7% in January to ~3.75M shares (about 3.3% of float) — increased bearish positioning can amplify downside pressure and intraday volatility.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.